Literature DB >> 34697449

HOTAIR/Sp1/miR-199a critically regulates cancer stemness and malignant progression of cutaneous squamous cell carcinoma.

Jia Chen1, Shu-Fen Hou1, Feng-Jie Tang1, Dai-Song Liu1, Zi-Zi Chen1, Hong-Lian Zhang1, Shao-Hua Wang2.   

Abstract

The long non-coding RNA (lncRNA), HOX antisense intergenic RNA (HOTAIR) is a well-characterized oncogene in multiple human cancers, but not in cutaneous squamous cell carcinoma (CSCC). In this study, we focused on investigating the potential role of HOTAIR in stemness of CSCC. By measuring its expression using RT-qPCR in CSCC vs. normal tissues, as well as in CSCC cell lines A431 or SCC13, A431- or SCC13-derived CSCC stem cells (CSCSCs), and normal skin fibroblasts (HSFs), we detected higher expression of HOTAIR in CSCC than in normal tissues, in recurrent than in non-recurrent CSCC tissues, in CSCCs and CSCSCs than in HSFs, and particularly, in CSCSCs than in CSCCs. Kaplan-Meier analysis suggested that higher expression of HOTAIR was positively correlated with worse overall survival of CSCC patients. Functional assays on colony formation, EdU incorporation, sphere formation, western blot on stem-cell biomarkers, and in vivo models showed that HOTAIR was essential in maintaining multiple stem cell phenotypes of CSCSCs in vitro and in vivo xenograft growth as well as metastasis. Mechanistically, HOTAIR directly interacted with and up-regulated Sp1. Sp1 then induced DNMT1-mediated promoter methylation and direct transcriptional repression of miR-199a-5p. Targeting Sp1 or DNMT1 further boosted the in vivo anti-tumor and anti-metastasis activities of targeting HOTAIR. In conclusion, HOTAIR, by up-regulating Sp1 and targeting miR-199a, promotes stemness and progression of CSCC. Targeting HOTAIR, Sp1 or the underlying mechanisms may thus benefit CSCC treatment.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34697449     DOI: 10.1038/s41388-021-02014-x

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma.

Authors:  Linda-Lotta Kokko; Saija Hurme; Sanna-Mari Maula; Kalle Alanen; Reidar Grénman; Ilpo Kinnunen; Sami Ventelä
Journal:  Oral Oncol       Date:  2011-04-22       Impact factor: 5.337

Review 2.  Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.

Authors:  Kyle A Burton; Kurt A Ashack; Amor Khachemoune
Journal:  Am J Clin Dermatol       Date:  2016-10       Impact factor: 7.403

Review 3.  HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer.

Authors:  Qing Tang; Swei Sunny Hann
Journal:  Cell Physiol Biochem       Date:  2018-05-24

4.  Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma.

Authors:  Michael Sand; Falk G Bechara; Daniel Sand; Thilo Gambichler; Stephan A Hahn; Michael Bromba; Eggert Stockfleth; Schapoor Hessam
Journal:  Epigenomics       Date:  2016-04-12       Impact factor: 4.778

5.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative.

Authors:  Adrian Biddle; Xiao Liang; Luke Gammon; Bilal Fazil; Lisa J Harper; Helena Emich; Daniela Elena Costea; Ian C Mackenzie
Journal:  Cancer Res       Date:  2011-06-17       Impact factor: 12.701

6.  Identification of Human Cutaneous Squamous Cell Carcinoma Cancer Stem Cells.

Authors:  Carlotta Olivero; Huw Morgan; Girish K Patel
Journal:  Methods Mol Biol       Date:  2019

7.  Long Non-Coding RNA HOTAIR Regulates the Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC) Subpopulation Enriched from Breast Cancer Cells.

Authors:  Jia Deng; Mengchang Yang; Rong Jiang; Ning An; Xiaoshan Wang; Bin Liu
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

8.  Cancer stem cell subpopulations in moderately differentiated head and neck cutaneous squamous cell carcinoma.

Authors:  Sabrina P Koh; Helen D Brasch; Jennifer de Jongh; Tinte Itinteang; Swee T Tan
Journal:  Heliyon       Date:  2019-08-16

9.  Long non-coding RNA HOTAIR functions as a competitive endogenous RNA to regulate PRAF2 expression by sponging miR-326 in cutaneous squamous cell carcinoma.

Authors:  Guo-Jun Yu; Yong Sun; Da-Wei Zhang; Peng Zhang
Journal:  Cancer Cell Int       Date:  2019-10-21       Impact factor: 5.722

Review 10.  The Roles of lncRNA in Cutaneous Squamous Cell Carcinoma.

Authors:  Yujia Wang; Bensen Sun; Xiang Wen; Dan Hao; Dan Du; Gu He; Xian Jiang
Journal:  Front Oncol       Date:  2020-02-28       Impact factor: 6.244

View more
  5 in total

1.  Association between long non-coding RNA HOTAIR polymorphism and lung cancer risk: A systematic review and meta-analysis.

Authors:  Chunlin Ke; Xuegang Feng; Jie Li; Siyu Chen; Xinyu Hu
Journal:  Exp Ther Med       Date:  2022-06-29       Impact factor: 2.751

Review 2.  Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models.

Authors:  Marika Quadri; Alessandra Marconi; Simran K Sandhu; Alexi Kiss; Tatiana Efimova; Elisabetta Palazzo
Journal:  Front Med (Lausanne)       Date:  2022-05-09

3.  Super Enhancer-Regulated LINC00094 (SERLOC) Upregulates the Expression of MMP-1 and MMP-13 and Promotes Invasion of Cutaneous Squamous Cell Carcinoma.

Authors:  Minna Piipponen; Pilvi Riihilä; Jaakko S Knuutila; Markku Kallajoki; Veli-Matti Kähäri; Liisa Nissinen
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

Review 4.  Non-coding RNAs in skin cancers:Biological roles and molecular mechanisms.

Authors:  Fei Liu; Shenglong Li
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

Review 5.  LINC00467: an oncogenic long noncoding RNA.

Authors:  Xuyu Chen; Qian Luo; Yanan Xiao; Jing Zhu; Yirao Zhang; Jie Ding; Juan Li
Journal:  Cancer Cell Int       Date:  2022-10-07       Impact factor: 6.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.